International Journal for Autism Challenges & Solution
Vol 1 Issue 2 (2024)
Pages (4 –17)

Available at www.emiratesscholar.com

The Role of Oxytocin in Autism Spectrum Disorder: Current Evidence and Therapeutic Implications

Geir Bjørklund[1], Ramesa Shafi Bhat[2]
bjorklund@conem.org[1],
Council for Nutritional and Environmental Medicine, Mo i Rana, Norway[1]
Biochemistry Department, College of Sciences, King Saud University, Riyadh, Saudi Arabia[2]

ARTICLE INFO

Published on 30th of December 2024
Doi: 10.54878/h8j48873

KEYWORDS

oxytocin, autism spectrum disorder, social cognition, clinical trials, neurobiology, personalized therapy

HOW TO CITE

The Role of Oxytocin in Autism Spectrum Disorder: Current Evidence and Therapeutic Implications. (2024). *International Journal for Autism Challenges & Solution*, 1(2), 4-17.

ABSTRACT

Oxytocin (OXT) is a neuropeptide implicated in social functioning, with potential therapeutic relevance in autism spectrum disorder (ASD). This review synthesizes current literature on OXT's effects in ASD, focusing on clinical trials, neurobiological mechanisms, and future directions. Studies highlight OXT's immediate impact on social cognition in typically developing adults and its variable outcomes in children with ASD. Neuroimaging findings elucidate OXT's effects on brain networks involved in social-emotional processing. Challenges, including individual variability and translational gaps, underscore the crucial role of personalized approaches in OXT research. Combining OXT with behavior therapy and probiotics shows promise. Future research should address gender differences, genetic influences, and long-term outcomes, emphasizing the importance of personalized approaches in OXT-based therapies.

Introduction

Oxytocin (OXT) is a neuropeptide predominantly synthesized in the hypothalamus, recognized for its central role in regulating social behavior and affiliative bonds [1]. Commonly referred to as the "love hormone" or "bonding molecule," it has sparked significant interest in neurobiology and neuropsychiatric disorders, notably autism spectrum disorder (ASD) [2]. ASD is a complex neurodevelopmental condition characterized by pervasive social deficits, including impaired social communication, reduced social reciprocity, and difficulties responding to social cues [3]. OXT's relevance to ASD stems from its pivotal role in mediating social behavior, making it a compelling target for investigating the neurobiological underpinnings of these deficits [4]. Extensive research has illuminated the interplay between OXT and social functioning, highlighting its capacity to modulate various facets of human behavior [5]. In typically developing individuals, OXT enhances social cognition, fosters trust, and facilitates interpersonal communication [6]. These effects underscore OXT's profound significance in shaping fundamental aspects of human interaction, a topic that continues to captivate researchers and clinicians alike. This review explores the multifaceted role of OXT in ASD, encompassing its molecular mechanisms, neurobiological effects, and clinical implications. By examining the current state of knowledge surrounding OXT in ASD, this paper aims to elucidate its potential as a therapeutic target and illuminate avenues for future research and clinical interventions. Comprehension of the complexities of OXT function in ASD is crucial for advancing social cognition and developing innovative approaches to enhance the quality of life for individuals affected by this condition.

Molecular Synthesis and Processing of Oxytocin

OXT is predominantly synthesized and released within the hypothalamus, specifically in oxytocinergic neurons in the paraventricular nucleus and supraoptic nucleus [7,8]. The biosynthesis of OXT begins with the transcription of the OXT gene into messenger RNA (mRNA) within these neurons. The transcribed mRNA carries the genetic information encoded by the OXT gene and serves as the template for protein synthesis [9]. In the cytoplasm, ribosomes translate the mRNA into preprooxytocin, a larger precursor protein containing a signal peptide directing it to the endoplasmic reticulum [10]. The signal peptide cleaves within the endoplasmic reticulum, transforming preprooxytocin into prooxytocin, a smaller intermediate protein containing the OXT peptide sequence [11]. Proper enzymatic processing of prooxytocin occurs in secretory vesicles, producing mature, bioactive OXT. Enzymes such as peptidases cleave prooxytocin to release the biologically active form of OXT [12]. A critical step in this maturation process is the enzymatic amidation of the OXT C-terminus by peptidylglycine alpha-amidating monooxygenase (PAM). PAM catalyzes the conversion of prooxytocin into amidated OXT, enhancing its biological activity and stability [13]. Dysregulation of PAM activity can lead to impaired oxytocinergic signaling, which has been implicated in contributing to social deficits observed in conditions like ASD. Reduced PAM function may decrease levels of mature OXT, impacting oxytocinergic signaling pathways involved in social bonding, emotional regulation, and social cognition. After synthesis and maturation, amidated OXT is stored in secretory vesicles within neurons and peripheral tissues [14]. Its release into the bloodstream or local tissues, triggered by neuronal activity in response to various stimuli, facilitates OXT's distribution throughout the body. This release influences peripheral tissues like mammary glands during lactation and the uterus during labor. The tightly regulated bioactivity and release of OXT contribute to its physiological and behavioral effects.

Mechanisms of Oxytocin Signaling and Neural Regulation

OXT exerts its physiological effects by binding to OXT receptors (OTRs) located on the surface of target cells, particularly within brain regions implicated in social behavior, such as the amygdala, nucleus accumbens, and prefrontal cortex. OTRs belong to the G-protein-coupled receptor family and initiate intracellular signaling upon OXT binding [15]. Upon binding, OTRs undergo conformational changes that activate heterotrimeric G proteins associated with OTRs, initiating downstream signaling pathways within neurons. One critical effect of OXT-OTR signaling is the modulation of cyclic adenosine monophosphate (cAMP) levels. OTR activation stimulates adenylate cyclase, leading to increased intracellular cAMP levels [16]. Elevated cAMP levels activate protein kinase A, influencing neuronal excitability and gene expression. In addition to cAMP signaling, OXT-OTR interaction regulates

intracellular calcium (Ca2+) levels. OTR activation triggers the release of intracellular calcium stores and the influx of extracellular calcium through voltage-gated calcium channels [17]. This transient rise in cytoplasmic calcium concentrations modulates synaptic transmission and neuronal excitability. Furthermore, OXT-OTR signaling activates mitogen-activated protein kinase pathways, including the extracellular signal-regulated kinase pathway. Activation of these pathways leads to the phosphorylation of transcription factors and other regulatory proteins, influencing gene expression that impacts synaptic plasticity and neuronal connectivity underlying social behaviors. Dysregulation of OXT synthesis pathways, often stemming from genetic variants or epigenetic modifications, can profoundly impact neural circuits critical for social behavior and emotional processing. Reduced OXT levels or impaired OXT signaling may compromise the formation and maintenance of social bonds, impair emotional recognition, and hinder empathic responses observed in conditions like ASD.

Genetic and Epigenetic Influences on Oxytocin Dysregulation and Social Behavior

Genetic factors are critical in OXT dysregulation, impacting various OXT synthesis and receptor function steps [18]. Variations in genes involved in OXT synthesis, such as PAM, can disrupt enzymatic processes necessary for OXT maturation from preprooxytocin. Similarly, polymorphisms within the OXT receptor (OXTR) gene can influence receptor expression levels or alter functional properties, affecting OXT-OTR signaling dynamics [19]. Epigenetic mechanisms, including DNA methylation and histone modifications, significantly influence OXT synthesis and receptor expression [20]. Altered epigenetic regulation of OXT-related genes can lead to enduring changes in gene expression patterns, affecting OXT availability and OXT receptor abundance within brain regions crucial for social behavior [20]. Specific genetic variations within OXTR have been linked to altered OXT receptor expression and function, impacting OXT signaling pathways associated with social behaviors observed in ASD [21-23]. Single nucleotide polymorphisms within OXTR can result in structural and functional changes affecting OXT receptor binding affinity and downstream signaling cascades [24]. Studies focusing on ASD genetics have associated specific OXTR variants with characteristic social behavior deficits in individuals with ASD, including impaired empathy, difficulties in social reciprocity, and deficits in social cognition [25,26]. These findings highlight a genetic basis for OXT dysregulation in ASD populations, underscoring the potential importance of gene profiling in tailoring therapeutic approaches.

Environmental Influences on Oxytocin Dysregulation in Autism Spectrum Disorder

Environmental factors profoundly influence OXT signaling and may contribute to the observed dysregulation of OXT in ASD [27]. These factors encompass diverse early life experiences, psychosocial stressors, exposure to toxins, and disruptions in gut microbiota, all potentially impacting the development and function of oxytocinergic systems in individuals with ASD [28,29]. Early life experiences, particularly prenatal and perinatal factors, play a critical role in shaping OXT signaling during crucial periods of brain development. Adverse prenatal conditions can have enduring effects on OXT synthesis and receptor expression, potentially contributing to the OXT dysregulation observed in individuals later diagnosed with ASD. Disruptions in OXT signaling during these crucial developmental stages may have long-lasting implications for social behavior and emotional regulation, possibly underpinning the social deficits seen in ASD [25,26]. Maternal infections during pregnancy, especially those involving immune activation, can influence OXT signaling in the developing fetus. Inflammatory responses triggered by maternal infections may alter OXT synthesis or receptor expression in the fetal brain, potentially contributing to atypical social behavior and emotional regulation observed in ASD [30]. Maternal stress during pregnancy can profoundly impact the developing fetus's OXT system. Elevated levels of maternal stress hormones, such as cortisol, can traverse the placenta and affect OXT synthesis and receptor expression in the fetal brain [31]. Prenatal exposure to chronic stress may disrupt the formation of oxytocinergic pathways, potentially predisposing individuals to social deficits later in life. Factors related to birth, such as birth trauma or prematurity, can also disrupt oxytocinergic pathways and contribute to OXT dysregulation [32]. Perinatal complications that compromise the oxygen supply to the brain or disrupt normal developmental processes may affect OXT synthesis, receptor expression, or neural circuitry involved in social functioning [32]. Chronic stress during early life or throughout development can significantly impact OXT levels and receptor sensitivity, potentially contributing to

observed OXT dysregulation in conditions like ASD [25]. Stress-related hormones like cortisol interact with oxytocinergic systems, influencing social behavior and emotional regulation. Prolonged exposure to stress during critical developmental periods can dysregulate OXT signaling by activating the hypothalamic-pituitary-adrenal axis and increasing cortisol production [33]. Cortisol can modulate OXT release and receptor expression, altering social responsiveness and emotional processing [34]. High cortisol levels can inhibit OXT synthesis and receptor binding, affecting social bonding, empathy, and emotional regulation. Dysregulated cortisol levels may disrupt the balance between stress responses and social behavior, potentially contributing to social deficits observed in ASD [25]. Exposure to adverse childhood experiences (ACEs), such as neglect, abuse, or parental separation, can impact OXT signaling and social development. ACEs are associated with dysregulated stress responses and altered oxytocinergic function, contributing to difficulties in forming social relationships and regulating emotions. Chronic stress-induced alterations in oxytocinergic systems have significant neurobiological consequences, potentially exacerbating social deficits in ASD by affecting brain regions involved in social cognition, empathy, and stress regulation [35]. Prenatal exposure to medications such as antidepressants or antipsychotics may indirectly interfere with OXT synthesis or receptor function in the developing fetus by modulating neurotransmitter systems or hormone levels [36]. This can impact social behavior and emotional development. Similarly, environmental toxins like pollutants, toxic metals (including lead and mercury), and endocrine-disrupting chemicals have been implicated in disrupting neurodevelopment and neurotransmitter systems, including OXT pathways, potentially contributing to OXT dysregulation observed in ASD. These toxins can directly impair OXT receptor expression or binding affinity, affecting social responsiveness and emotional processing [36]. Exposure to such toxins during critical neurodevelopmental stages can disrupt neuronal connectivity and neurotransmitter balance, further impacting social behavior and emotional regulation. Pollutants and chemicals with endocrine-disrupting properties can also influence hormone regulation, including OXT, which is crucial in social bonding and behavior. In individuals with ASD, dysregulated OXT signaling may contribute to social deficits and impairments in social cognition and interpersonal relationships. Therefore, the impact of prenatal and postnatal exposures on oxytocinergic systems is essential for elucidating the etiology of neurodevelopmental disorders. The gut microbiota, comprising trillions of microorganisms inhabiting the gastrointestinal tract, plays a pivotal role in neurotransmitter metabolism and gut-brain communication through the microbiota-gut-brain axis. The complex interplay between gut microbiota and neurotransmitter systems, particularly OXT, is emerging as a critical factor in neurodevelopment and social behavior, with implications for disorders like ASD [37]. Dysbiosis, characterized by disruptions in gut microbiota composition, can profoundly impact neurotransmitter dynamics, including OXT regulation [38]. The gut microbiota influences OXT through various mechanisms. Microbial-derived metabolites, such as short-chain fatty acids and neurotransmitter precursors, can modulate neuronal signaling and neurotransmitter synthesis, affecting social behavior and emotional responses [39]. Moreover, alterations in gut microbiota composition driven by dietary factors, antibiotic use, or environmental influences can perturb OXT levels and receptor sensitivity. Dysbiosis-induced changes in microbial communities may disrupt oxytocinergic pathways, contributing to the social deficits and emotional dysregulation observed in individuals with ASD [40]. Microbial-derived metabolites mediate bidirectional communication between the gut microbiota and the central nervous system and can directly influence neurodevelopment and neurotransmitter systems [41]. For instance, microbial metabolites may impact OXT synthesis, release, or receptor function, ultimately influencing social cognition and interpersonal relationships. Recognizing the impact of environmental influences on OXT signaling has important implications for intervention strategies in ASD. Targeted interventions aimed at reducing psychosocial stress, minimizing exposure to environmental toxins, or promoting gut health through probiotics and dietary modifications could help modulate oxytocinergic systems and improve social functioning in individuals with ASD.

Oxytocin's Impact on Social Functioning in Typically Developing Adults

OXT profoundly influences social functioning in typically developing adults by shaping cognitive and behavioral processes essential for interpersonal interactions. Research has elucidated the immediate effects of OXT administration on various facets of social behavior, highlighting its role as a facilitator of

social cognition and emotional processing [42]. OXT enhances social cognition, including the perception, interpretation, and response to social cues. Studies demonstrate that OXT increases sensitivity to facial expressions, particularly improving the recognition of emotions such as trust, happiness, and empathy [43]. This heightened social sensitivity fosters more accurate and empathetic interpersonal interactions, ultimately improving overall social functioning. Another critical domain influenced by OXT is emotion recognition. Research indicates that OXT administration enhances the accurate identification and interpretation of emotional expressions in others, fostering greater empathy and emotional resonance during social interactions. Individuals under the influence of OXT demonstrate enhanced emotional empathy, reflecting a more profound comprehension and sharing of others' emotional experiences [43]. Moreover, OXT promotes social reciprocity by modulating prosocial behaviors and fostering trust and cooperation. Studies have shown that OXT administration increases interpersonal trust and generosity, leading to more cooperative and mutually beneficial interactions. This effect is likely mediated by OXT's influence on brain regions involved in reward processing and social decision-making [44]. The underlying mechanisms through which OXT influences social functioning involve its interaction with brain regions such as the amygdala, prefrontal cortex, and insula, which are crucial for social cognition and emotional processing. OXT modulates neural activity within these regions, enhancing their responsiveness to social stimuli and promoting adaptive social behaviors [45]. OXT's impact on social functioning in typically developing adults has important implications for elucidating the neurobiology of social behavior and interpersonal relationships. Further research exploring OXT's role in social deficits observed in conditions like ASD may inform novel therapeutic strategies aimed at enhancing social cognition and emotional regulation.

Oxytocin Studies in Autism Spectrum Disorder

Research exploring OXT in ASD reveals varied outcomes across age groups, highlighting the complexity of OXT interventions in this population. Clinical trials in children with ASD demonstrate mixed results, with some studies reporting positive effects on social responsiveness and reductions in repetitive behaviors following OXT treatment [46]. However, response variability is influenced by participant characteristics, dosing regimens, and the heterogeneous nature of ASD. Age significantly influences OXT treatment responses in children with ASD, with younger children often showing more pronounced improvements in social behaviors [47]. Safety considerations are paramount, especially in pediatric populations, underscoring the need for careful monitoring and evaluation of OXT interventions. In adults with ASD, OXT trials demonstrate potential benefits on core symptoms such as enhanced social behavior and reduced repetitive behaviors. However, not all studies consistently show short-term benefits, likely due to individual response variability and the complexity of ASD symptoms. Long-term effects of OXT in adults with ASD remain uncertain, with some studies reporting sustained improvements in specific behaviors like reduced repetitive behaviors and positive mood. Nevertheless, evidence on long-term benefits for social reciprocity and overall functioning is inconsistent, necessitating further investigation into the optimal timing and duration of OXT interventions. OXT interventions also show promise in specific behavioral domains like emotion recognition, potentially modulating neural circuits implicated in ASD symptoms [48]. Meta-analyses across age groups demonstrate modest improvements in social functioning post-OXT administration, particularly in emotion recognition and social communication. However, effects vary among adult populations, indicating age-related differences in treatment response and highlighting the need for tailored interventions. The epidemiology of OXT levels in ASD reveals variations compared to neurotypical individuals, with lower OXT levels observed in children and adults with ASD, particularly those with severe social deficits. Despite the variability, OXT deficiencies or dysregulation may be present in a subset of individuals, suggesting a potential role in ASD pathophysiology [49].

Awareness of possible OXT deficiencies is crucial for developing targeted interventions tailored to specific ASD subgroups based on their OXT profiles. Further research with larger sample sizes and longitudinal designs is essential to elucidate OXT levels in ASD and optimize OXT interventions for improving social functioning and quality of life.

Neurobiological Underpinnings of Oxytocin Effects

OXT influences social behavior and emotional processing through interactions within neural circuits implicated in social-emotional processing. Neuroimaging studies have provided valuable insights

into the neurobiological mechanisms underlying OXT effects, revealing brain activation and connectivity changes following OXT administration. Functional magnetic resonance imaging investigations have demonstrated changes in brain activation patterns associated with OXT administration [50]. Key brain regions involved in social cognition, including the amygdala, insula, and prefrontal cortex, exhibit increased activation in response to OXT [51]. These brain areas are critical in processing social cues, regulating emotional reactions, and facilitating interpersonal interactions. OXT modulates amygdala responsiveness, a pivotal brain region in emotional processing and threat detection. Increased amygdala activation following OXT administration is associated with reduced anxiety and heightened social approach behaviors, highlighting OXT's role in promoting positive social interactions [52]. Furthermore, OXT influences the functional connectivity of neural networks underlying social-emotional processing. Studies have revealed enhanced connectivity between brain regions involved in reward processing, such as the nucleus accumbens and ventromedial prefrontal cortex, following OXT administration. This improved connectivity fosters feelings of trust, empathy, and social bonding [53]. OXT modulates interactions between the brain's reward system and socioemotional processing networks, facilitating the interpretation of social cues and regulation of emotional responses. OXT-induced changes in neural connectivity contribute to improvements in social cognition, emotional empathy, and social reciprocity observed in response to OXT treatment. Significantly, the neurobiological effects of OXT extend beyond localized changes in brain activation to encompass widespread alterations in neural networks critical for social functioning. Neuroimaging studies elucidate the neural underpinnings of OXT effects, providing a mechanistic framework for its therapeutic potential in enhancing social behavior and emotional regulation. These insights into OXT's neurobiological effects underscore its role as a promising target for interventions to improve social functioning and emotional well-being in individuals with neurodevelopmental and neuropsychiatric conditions [50].

Potential Dysregulation of the Oxytocin System in Autism Spectrum Disorder

The OXT system has emerged as a critical player in the pathophysiology of ASD, with growing evidence suggesting potential dysregulation of OXT levels and signaling in affected individuals. Several studies have reported lower baseline levels of circulating OXT in individuals with ASD compared to typically developing individuals, indicating alterations in OXT synthesis, release, or receptor functioning may contribute to the social deficits observed in ASD [54]. Dysregulation of the OXT system may manifest as impaired social bonding, reduced empathy, and difficulties in interpreting social cues, which are core features of ASD. [55-57] The mechanisms underlying OXT dysregulation in ASD are likely multifactorial and remain unclear. Genetic factors, epigenetic modifications, and environmental influences may all contribute to disrupted oxytocinergic signaling in individuals with ASD [58-59]. These factors are critical for elucidating the etiology of social impairments in ASD and developing targeted interventions aimed at restoring OXT homeostasis. The relationship between OXT dysregulation and social impairments in ASD is complex and bidirectional. Dysfunctional oxytocinergic signaling may contribute to social deficits by impairing the ability to form and maintain social relationships, recognize emotional cues, and engage in reciprocal social interactions. Conversely, the social challenges inherent in ASD may further exacerbate OXT dysregulation through altered social experiences and interactions. Preclinical studies in animal models of ASD have provided insights into the causal relationship between OXT dysregulation and social behaviors [60-61]. Manipulations of the OXT system, such as OXT administration or genetic modifications affecting OXT receptor expression, have been shown to influence social behaviors resembling ASD-like phenotypes. These studies highlight the potential for targeting the OXT system as a therapeutic strategy to ameliorate social deficits in ASD.

Intranasal Oxytocin Therapy

Intranasal OXT therapy represents a promising intervention for addressing social interaction impairments in individuals with ASD [62]. A growing body of research is exploring its efficacy, bioavailability, pharmacokinetics, and long-term effects. Numerous clinical trials have investigated the therapeutic effects of intranasal OXT on social behaviors and core symptoms of ASD. Intranasal administration enables direct delivery of OXT to the brain via the nasal mucosa, circumventing the blood-brain barrier and enhancing penetration into the central nervous system [63-65]. Studies evaluating the efficacy of intranasal OXT in improving social

functioning in ASD have reported mixed results. Some trials have demonstrated positive effects, including increased eye contact, enhanced emotion recognition, and improved social reciprocity. However, the magnitude and consistency of these effects vary across studies and individuals, underscoring the need for further investigation into factors influencing OXT responsiveness in ASD. Intranasal OXT exhibits favorable bioavailability and rapid absorption into the systemic circulation [66]. Following administration, OXT reaches peak plasma levels within minutes, with detectable concentrations in cerebrospinal fluid and brain regions involved in social behavior [67]. This efficient delivery method allows for targeted modulation of OXT signaling within neural circuits associated with social-emotional processing. The pharmacokinetics of intranasal OXT are characterized by a relatively short half-life, necessitating frequent dosing to maintain therapeutic levels. Researchers are exploring strategies such as dose titration and formulation modifications to enhance therapeutic efficacy and prolong the duration of OXT effects. Longitudinal studies investigating the long-term effects of intranasal OXT therapy in ASD are ongoing. While short-term benefits have been documented, questions remain regarding the sustainability and enduring impact of intranasal OXT on social behavior and quality of life. Preliminary evidence suggests that sustained OXT treatment may lead to persistent improvements in specific social domains like emotion recognition and communication. However, further research is needed to assess the durability of these effects and potential risks associated with prolonged OXT exposure. Intranasal OXT therapy holds promise as a targeted intervention for addressing social interaction impairments in ASD [68]. Considerations of bioavailability, pharmacokinetics, and long-term effects are critical in optimizing its therapeutic utility and advancing personalized treatment approaches for individuals with ASD. Future research efforts should focus on elucidating the underlying mechanisms of OXT action, refining dosing regimens, and identifying predictors of treatment response to maximize clinical outcomes and improve the quality of life for individuals affected by ASD.

Safety and Long-Term Considerations of Oxytocin Therapy in Autism Spectrum Disorder

OXT has emerged as a promising therapeutic agent for ASD, yet considerations regarding its safety profile and long-term implications are critical for informed clinical use and management. Clinical trials investigating OXT in ASD have generally reported a favorable safety profile with minimal adverse effects [69]. Commonly reported side effects include mild gastrointestinal symptoms (e.g., nausea and diarrhea), transient headache, and nasal irritation (related to intranasal administration). These effects are typically mild and transient, with no serious or long-lasting consequences observed in most individuals. Despite OXT's safety, ongoing monitoring and assessment of potential side effects are essential, especially with chronic or high-dose administration. Long-term safety data are limited, necessitating continued surveillance to identify any emerging concerns associated with prolonged OXT exposure [69]. The long-term implications of chronic OXT administration in ASD management remain an active area of investigation and debate. While short-term benefits on social behavior and emotional processing have been documented, questions persist regarding the sustainability and durability of these effects. Concerns about tolerance, desensitization of OXT receptors, and alterations in endogenous OXT production with chronic use have been raised [70]. Preclinical studies in animal models suggest that prolonged OXT exposure may lead to the downregulation of OXT receptors, potentially diminishing therapeutic efficacy. Furthermore, the impact of chronic OXT administration on neurodevelopment, hormonal regulation, and social adaptation requires careful consideration [71]. To address these concerns, longitudinal studies assessing the effects of chronic OXT therapy on neurobiological, cognitive, and behavioral outcomes in individuals with ASD are needed. Evaluating the risks and benefits associated with long-term OXT use will inform clinical decision-making and guide the development of evidence-based guidelines for optimal ASD management [72]. While OXT holds promise as a therapeutic intervention for addressing social deficits in ASD, safety considerations and long-term implications of OXT administration require careful attention. Continued research efforts aimed at elucidating the safety profile and neurobiological effects of chronic OXT therapy will advance therapeutic potential and inform best practices for personalized treatment strategies in individuals with ASD. Collaborative efforts between researchers, clinicians, and regulatory agencies are essential to ensure the safe and effective use of OXT as a targeted intervention for improving social functioning and quality of life in individuals affected by ASD.

Challenges in Oxytocin Research for Autism Spectrum Disorder

Investigating OXT as a potential treatment for ASD and other social deficits presents several methodological challenges and translational gaps that warrant careful consideration in research and clinical practice. ASD is a heterogeneous condition characterized by diverse symptom profiles and severity levels. Variability in participant characteristics across OXT trials, including age, gender, and comorbidities, can confound study outcomes and limit generalizability [73]. Many OXT trials in ASD have utilized small sample sizes, potentially compromising statistical power and the ability to detect meaningful treatment effects. Larger, well-powered studies are needed to replicate findings and establish robust evidence for OXT efficacy. Reliance on subjective outcome measures, such as parent- or caregiver-reported assessments of social behavior, may introduce biases in OXT trials. Objective, standardized measures of social functioning and behavioral outcomes are needed to ensure rigor and reliability in evaluating treatment effects. Variability in OXT dosing regimens and administration protocols across studies may contribute to inconsistent findings. Optimizing OXT delivery methods, dosages, and treatment durations is essential for maximizing therapeutic efficacy and minimizing variability in treatment response. The tendency to publish positive results while omitting negative or null findings may skew the overall perception of OXT efficacy in ASD. Reporting study outcomes, including positive and negative results, is critical for minimizing publication bias and promoting transparency in research.

OXT trials often assess treatment effects in controlled laboratory settings, which may not fully capture the complexities of real-life social interactions. Translating experimental findings to real-world contexts, such as home, school, or community settings, is essential for evaluating the practical impact of OXT interventions on daily functioning. Generalizing OXT effects observed in experimental settings to diverse populations and ecological contexts remains challenging [74]. Individual variability, environmental influences, and social context may modulate treatment response and necessitate personalized treatment approaches. The durability and long-term effects of OXT treatment on social behavior and quality of life in individuals with ASD are not well understood [69]. Longitudinal studies assessing the sustained efficacy and real-world impact of OXT interventions are needed to inform clinical decision-making and guide treatment recommendations. Addressing methodological limitations and translational gaps in OXT research is essential for advancing OXT's therapeutic potential in ASD. Collaborative efforts among researchers, clinicians, and stakeholders are needed to overcome these challenges, promote methodological rigor, and facilitate the translation of research findings into practical, evidence-based interventions for individuals affected by ASD. By addressing these challenges, the clinical utility of OXT can be optimized, and the outcomes for individuals with social deficits and related neuropsychiatric conditions can be improved [58-60].

Combination Therapies with Oxytocin

Exploring combination therapies involving OXT alongside adjunctive treatments, such as behavior therapy and probiotics, represents a promising avenue for enhancing therapeutic outcomes in ASD and related conditions [75]. Behavior therapy, including applied behavior analysis (ABA) and social skills training, is commonly used in conjunction with OXT interventions to target specific social deficits in individuals with ASD [76]. The combination of OXT and behavior therapy aims to enhance treatment efficacy by addressing neurobiological and behavioral aspects of social functioning. Behavioral interventions provide structured guidance and support for developing social skills, while OXT modulates underlying neurobiological processes associated with social behavior. Emerging research suggests a potential link between gut microbiota and social behavior, with probiotics hypothesized to influence brain function and behavior via the gut-brain axis [77]. Combined therapies involving OXT and probiotics aim to leverage the bidirectional communication between the gut microbiome and central nervous system to optimize treatment outcomes in ASD. Probiotics may enhance the bioavailability and efficacy of OXT by modulating gut health and immune function. Clinical trials investigating combined therapies with OXT and adjunctive treatments are underway to assess treatment efficacy and synergistic effects on social behavior and quality of life in individuals with ASD. These studies aim to elucidate the additive or complementary benefits of combining OXT with behavior therapy or probiotics in improving specific outcomes related to social functioning and adaptive behavior. Emerging research seeks to elucidate the underlying mechanisms of action and

neurobiological interactions associated with combined therapies involving OXT. By exploring the synergistic effects of OXT and adjunctive treatments on neural circuits, neurotransmitter systems, and immune function, researchers aim to identify novel targets for personalized interventions and optimize treatment strategies for individuals with ASD. Combination therapies involving OXT alongside adjunctive treatments represent a promising approach for addressing the complex nature of social deficits in ASD [78-79]. Clinical trials and emerging research on combined therapeutic approaches aim to leverage synergistic effects and capitalize on the complementary mechanisms of action associated with OXT and adjunctive treatments. By integrating behavioral, microbial, and neurobiological perspectives, combined therapies offer novel insights into the development of tailored interventions and personalized treatment strategies for individuals affected by ASD and related social impairments. Continued research efforts are needed to establish evidence-based guidelines and optimize the clinical utility of combined therapies in improving outcomes for individuals with ASD.

Individual Variability and Modulators of Oxytocin Response

OXT interventions in ASD are significantly influenced by individual variability in factors such as gender, genetics, and environmental influences [80]. Gender differences play a substantial role in shaping OXT responsiveness, with emerging evidence indicating differential effects of OXT interventions based on biological sex [82]. Studies suggest that OXT may exert varying effects on social behavior and emotional processing in males and females, reflecting sex-specific neurobiological mechanisms underlying OXT signaling. This highlights the importance of considering sex-based differences in treatment response and tailoring interventions accordingly to optimize therapeutic outcomes [83]. Genetic factors also contribute to individual differences in OXT response, with variations in OXTR and synthesis pathways influencing treatment outcomes [84]. Polymorphisms in OXTR genes have been associated with differential OXT receptor expression and binding affinity, which can affect sensitivity to OXT interventions. Genetic profiling may help identify individuals more likely to benefit from OXT therapy and inform personalized treatment strategies based on genetic markers [19,24]. In addition to genetic influences, baseline levels of endogenous OXT also play a role in modulating response to exogenous OXT interventions. Individuals with lower baseline OXT levels or dysregulated oxytocinergic signaling may exhibit different treatment responses compared to those with normal OXT levels. Furthermore, environmental factors such as early life experiences, social upbringing, and psychosocial stressors can significantly impact OXT responsiveness and treatment outcomes. Adverse environmental exposures may influence OXT synthesis, receptor expression, and neural circuitry involved in social behavior, thus influencing the efficacy of OXT interventions. However, personalized treatment strategies based on individual variability in OXT response hold promise for optimizing therapeutic outcomes and improving treatment efficacy in ASD. The potential of precision medicine approaches, which leverage genetic, neurobiological, and environmental factors to tailor OXT interventions to the unique needs and characteristics of individuals with ASD, gives hope for the future. Identifying biomarkers associated with OXT response may facilitate predictive modeling and treatment optimization, enabling the stratification of patient subgroups based on OXT responsiveness and guiding targeted interventions [84].

Future directions in OXT research should prioritize the integration of multidimensional factors influencing treatment response and embrace a precision medicine framework to enhance the effectiveness of OXT-based therapies in addressing social deficits and related symptoms in ASD.

Conclusion

OXT is critical in modulating neural circuits associated with social cognition, empathy, and social bonding, impacting behaviors relevant to ASD. Neuroimaging studies have identified specific brain regions and neurotransmitter systems affected by OXT. Clinical trials have shown modest improvements in social behaviors and emotion recognition, particularly in adults with ASD, although treatment responses vary. Personalized approaches, including adjunctive therapies such as behavioral interventions and probiotics, may enhance the effectiveness of OXT. Factors such as gender, genetics, and baseline OXT levels influence individual responses, underscoring the need for precision medicine. Future research should evaluate long-term effectiveness and focus on improving daily functioning to optimize OXT-based treatments. This emphasis on long-term effectiveness evaluation is

crucial, as it will enhance the knowledge of the sustained benefits of OXT-based therapies in ASD, thereby optimizing treatment strategies and improving outcomes for individuals with ASD.

References

1. Ross HE, Young LJ. Oxytocin and the neural mechanisms regulating social cognition and affiliative behavior. Front Neuroendocrinol. 2009;30(4):534-547. doi:10.1016/j.yfrne.2009.05.004

2. Kirsch P. Oxytocin in the socioemotional brain: implications for psychiatric disorders. Dialogues Clin Neurosci. 2015;17(4):463-476. doi:10.31887/DCNS.2015.17.4/pkirsch

3. Hodges H, Fealko C, Soares N. Autism spectrum disorder: definition, epidemiology, causes, and clinical evaluation. Transl Pediatr. 2020;9(Suppl 1):S55-S65. doi:10.21037/tp.2019.09.09

4. Zhao F, Zhang H, Wang P, et al. Oxytocin and serotonin in the modulation of neural function: Neurobiological underpinnings of autism-related behavior. Front Neurosci. 2022;16:919890. Published 2022 Jul 22. doi:10.3389/fnins.2022.919890

5. Leithead AB, Tasker JG, Harony-Nicolas H. The interplay between glutamatergic circuits and oxytocin neurons in the hypothalamus and its relevance to neurodevelopmental disorders. J Neuroendocrinol. 2021;33(12):e13061. doi:10.1111/jne.13061

6. Spengler FB, Scheele D, Marsh N, et al. Oxytocin facilitates reciprocity in social communication. Soc Cogn Affect Neurosci. 2017;12(8):1325-1333. doi:10.1093/scan/nsx061

7. Arakawa H. Dynamic regulation of oxytocin neuronal circuits in the sequential processes of prosocial behavior in rodent models. Curr Res Neurobiol. 2021;2:100011.

8. Landgraf R, Neumann ID. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front Neuroendocrinol. 2004;25(2–4):150–76

9. Scordalakes EM, Yue C, Gainer H. Experimental approaches for the study of oxytocin and vasopressin gene expression in the central nervous system. Prog Brain Res. 2008;170:43-51. doi:10.1016/S0079-6123(08)00404-4

10. Reid DW, Nicchitta CV. Diversity and selectivity in mRNA translation on the endoplasmic reticulum. Nat Rev Mol Cell Biol. 2015;16(4):221-231. doi:10.1038/nrm3958

11. Makani V, Sultana R, Sie KS, et al. Annexin A1 complex mediates oxytocin vesicle transport. J Neuroendocrinol. 2013;25(12):1241-1254. doi:10.1111/jne.12112

12. Merkler DJ, Hawley AJ, Eipper BA, Mains RE. Peptidylglycine α-amidating monooxygenase as a therapeutic target or biomarker for human diseases. Br J Pharmacol. 2022;179(13):3306-3324. doi:10.1111/bph.15815

13. Dhivya Kumar, Daniela Strenkert, Ramila S Patel-King, Michael T Leonard, Sabeeha S Merchant, Richard E Mains, Stephen M King, Betty A Eipper (2017) A bioactive peptide amidating enzyme is required for ciliogenesis eLife 6:e25728

14. Eiden LE, Hernández VS, Jiang SZ, Zhang L. Neuropeptides and small-molecule amine transmitters: cooperative signaling in the nervous system. Cell Mol Life Sci. 2022;79(9):492. Published 2022 Aug 23. doi:10.1007/s00018-022-04451-7

15. Triana-Del Rio R, Ranade S, Guardado J, LeDoux J, Klann E, Shrestha P. The modulation of emotional and social behaviors by oxytocin signaling in limbic network. Front Mol Neurosci. 2022;15:1002846. Published 2022 Nov 17. doi:10.3389/fnmol.2022.1002846

16. Gárriz A, Morokuma J, Toribio D, Zoukhri D. Role of the adenylate cyclase/cyclic AMP pathway in oxytocin-induced lacrimal gland myoepithelial cells contraction. Exp Eye Res. 2023;233:109526. doi:10.1016/j.exer.2023.109526

17. Howe AK. Cross-talk between calcium and protein kinase A in the regulation of cell migration. Curr Opin Cell Biol. 2011;23(5):554-561. doi:10.1016/j.ceb.2011.05.006

18. Pierzynowska K, Gaffke L, Żabińska M, et al. Roles of the Oxytocin Receptor (OXTR) in Human Diseases. Int J Mol Sci. 2023;24(4):3887. Published 2023 Feb 15. doi:10.3390/ijms24043887

19. Dadds MR, Moul C, Cauchi A, Dobson-Stone C, Hawes DJ, Brennan J, Urwin R, Ebstein RE. Polymorphisms in the oxytocin receptor gene are associated with the development of psychopathy. Dev

Psychopathol. 2014 Feb;26(1):21-31. doi: 10.1017/S0954579413000485. Epub 2013 Sep 23. PMID: 24059750.

20. Kumsta R, Hummel E, Chen FS, Heinrichs M. Epigenetic regulation of the oxytocin receptor gene: implications for behavioral neuroscience. Front Neurosci. 2013; 7:83. Published 2013 May 23. doi:10.3389/fnins.2013.00083

21. Andari E., Duhamel J. R., Zalla T., Herbrecht E., Leboyer M., Sirigu A. (2010). Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc. Natl. Acad. Sci. U.S.A. 107, 4389–4394 10.1073/pnas.0910249107

22. Gregory S. G., Connelly J. J., Towers A. J., Johnson J., Biscocho D., Markunas C. A., et al. (2009). Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. BMC Medicine 7:62 10.1186/1741-7015-7-62

23. Guastella A. J., Einfeld S. L., Gray K. M., Rinehart N. J., Tonge B. J., Lambert T. J., et al. (2010). Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol. Psychiatry 67, 692–694 10.1016/j.biopsych.2009.09.020

24. Chen F. S., Kumsta R., Von Dawans B., Monakhov M., Ebstein R. P., Heinrichs M. (2011). Common oxytocin receptor gene (OXTR) polymorphism and social support interact to reduce stress in humans. Proc. Natl. Acad. Sci. U.S.A. 108, 19937–19942 10.1073/pnas.1113079108

25. Heinrichs M., Von Dawans B., Domes G. (2009). Oxytocin, vasopressin, and human social behavior. Front. Neuroendocrinol. 30, 548–557 10.1016/j.yfrne.2009.05.005

26. Ebstein R. P., Knafo A., Mankuta D., Chew S. H., Lai P. S. (2012). The contributions of oxytocin and vasopressin pathway genes to human behavior. Horm. Behav. 61, 359–379

27. Karimi P, Kamali E, Mousavi SM, Karahmadi M. Environmental factors influencing the risk of autism. J Res Med Sci. 2017;22:27. Published 2017 Feb 16. doi:10.4103/1735-1995.200272

28. Curley JP, Jensen CL, Mashoodh R, Champagne FA. Social influences on neurobiology and behavior: Epigenetic effects during development. Psychoneuroendocrinology. 2011;36:352–71.

29. Gudsnuk K, Champagne FA. Epigenetic influence of stress and the social environment. Ilar J. 2012;53:279–88. [doi: 10.1093/ilar.53.3-4.279]

30. Zawadzka A, Cieślik M, Adamczyk A. The Role of Maternal Immune Activation in the Pathogenesis of Autism: A Review of the Evidence, Proposed Mechanisms and Implications for Treatment. Int J Mol Sci. 2021;22(21):11516. Published 2021 Oct 26. doi:10.3390/ijms222111516

31. Jagtap A, Jagtap B, Jagtap R, Lamture Y, Gomase K. Effects of Prenatal Stress on Behavior, Cognition, and Psychopathology: A Comprehensive Review. Cureus. 2023;15(10):e47044. Published 2023 Oct 14. doi:10.7759/cureus.47044

32. Walter MH, Abele H, Plappert CF. The Role of Oxytocin and the Effect of Stress During Childbirth: Neurobiological Basics and Implications for Mother and Child. Front Endocrinol (Lausanne). 2021;12:742236. Published 2021 Oct 27. doi:10.3389/fendo.2021.742236

33. Herman JP, McKlveen JM, Ghosal S, et al. Regulation of the Hypothalamic-Pituitary-Adrenocortical Stress Response. Compr Physiol. 2016;6(2):603-621. Published 2016 Mar 15. doi:10.1002/cphy.c150015

34. Donadon MF, Martin-Santos R, Osório FL. The Associations Between Oxytocin and Trauma in Humans: A Systematic Review. Front Pharmacol. 2018;9:154. Published 2018 Mar 1. doi:10.3389/fphar.2018.00154

35. Jin Y, Song D, Yan Y, Quan Z, Qing H. The Role of Oxytocin in Early-Life-Stress-Related Neuropsychiatric Disorders. Int J Mol Sci. 2023;24(13):10430. Published 2023 Jun 21. doi:10.3390/ijms241310430

36. McCormack SE, Blevins JE, Lawson EA. Metabolic Effects of Oxytocin. Endocr Rev. 2020;41(2):121-145. doi:10.1210/endrev/bnz012

37. Chen Y, Xu J, Chen Y. Regulation of Neurotransmitters by the Gut Microbiota and Effects on Cognition in Neurological Disorders. Nutrients. 2021;13(6):2099. Published 2021 Jun 19. doi:10.3390/nu13062099

38. L. Yuan, S. Liu, X. Bai, Y. Gao, G. Liu, X. Wang, D. Liu, T. Li, A. Hao, Z. Wang Oxytocin inhibits lipopolysaccharide-induced inflammation in

microglial cells and attenuates microglial activation in lipopolysaccharide-treated mice J. Neuroinflammation, 13 (1) (2016)

39. A. Sarkar, S. Harty, K.V.A. Johnson, A.H. Moeller, R.N. Carmody, S.M. Lehto, S.E. Erdman, R.I.M. Dunbar, P.W.J. Burnet The role of the microbiome in the neurobiology of social behaviourBiol. Rev., 95 (5) (2020), pp. 1131-1166, 10.1111/brv.12603

40. M. Sgritta, S.W. Dooling, S.A. Buffington, E.N. Momin, M.B. Francis, R.A. Britton, M. Costa-MattioliMechanisms underlying microbial-mediated changes in social behavior in mouse models of autism spectrum disorder Neuron, 101 (2) (2019), pp. 246-259 e246

41. Q. Tan, C.E. Orsso, E.C. Deehan, J.Y. Kung, H.M. Tun, E. Wine, K.L. Madsen, L. Zwaigenbaum, A.M. HaqqProbiotics, prebiotics, synbiotics, and fecal microbiota transplantation in the treatment of behavioral symptoms of autism spectrum disorder: a systematic review Autism Res., 14 (9) (2021), pp. 1820-1836,

42. Horta M, Pehlivanoglu D, Ebner NC. The Role of Intranasal Oxytocin on Social Cognition: An Integrative Human Lifespan Approach. Curr Behav Neurosci Rep. 2020 Dec;7(4):175-192. doi: 10.1007/s40473-020-00214-5. Epub 2020 Sep 12.

43. Krug I, Fung S, Liu S, Treasure J, Huang C, Felmingham K, Fuller-Tyszkiewicz M, McConchie O. The impact of oxytocin on emotion recognition and trust: Does disordered eating moderate these relationships? PLoS One. 2024 May 31;19(5):e0303824. doi: 10.1371/journal.pone.0303824.

44. Wigton R, Radua J, Allen P, Averbeck B, Meyer-Lindenberg A, McGuire P, Shergill SS, Fusar-Poli P. Neurophysiological effects of acute oxytocin administration: systematic review and meta-analysis of placebo-controlled imaging studies. J Psychiatry Neurosci. 2015 Jan;40(1):E1-22. doi: 10.1503/jpn.130289.

45. Rigney N, de Vries GJ, Petrulis A, Young LJ. Oxytocin, Vasopressin, and Social Behavior: From Neural Circuits to Clinical Opportunities. Endocrinology. 2022 Sep 1;163(9):bqac111. doi: 10.1210/endocr/bqac111.

46. Zhao W, Le J, Liu Q, Zhu S, Lan C, Zhang Q, Zhang Y, Li Q, Kou J, Yang W, Zhang R, Becker B, Zhang L, Kendrick KM. A clustering approach identifies an Autism Spectrum Disorder subtype more responsive to chronic oxytocin treatment. Transl Psychiatry. 2024 Jul 29;14(1):312. doi: 10.1038/s41398-024-03025-4.

47. Parker KJ, Oztan O, Libove RA, Sumiyoshi RD, Jackson LP, Karhson DS, Summers JE, Hinman KE, Motonaga KS, Phillips JM, Carson DS, Garner JP, Hardan AY. Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):8119-8124. doi: 10.1073/pnas.1705521114. Epub 2017 Jul 10.

48. Wang L, Wang B, Wu C, Wang J, Sun M. Autism Spectrum Disorder: Neurodevelopmental Risk Factors, Biological Mechanism, and Precision Therapy. Int J Mol Sci. 2023 Jan 17;24(3):1819. doi: 10.3390/ijms24031819. PMID: 36768153; PMCID: PMC9915249.

49. Haaf R, Brandi ML, Albantakis L, Lahnakoski JM, Henco L, Schilbach L. Peripheral oxytocin levels are linked to hypothalamic gray matter volume in autistic adults: a cross-sectional secondary data analysis. Sci Rep. 2024 Jan 16;14(1):1380. doi: 10.1038/s41598-023-50770-5..

50. Febo M, Numan M, Ferris CF. Functional magnetic resonance imaging shows oxytocin activates brain regions associated with mother-pup bonding during suckling. J Neurosci. 2005 Dec 14;25(50):11637-44. doi: 10.1523/JNEUROSCI.3604-05.2005.

51. Li M, Fleming AS (2003) The nucleus accumbens shell is critical for normal expression of pup-retrieval in postpartum female rats. Behav Brain Res 145: 99–111.

52. Quintana, D.S., Rokicki, J., van der Meer, D., Alnaes, D., Kaufmann, T., Cordova-Palomera, A., Dieset, I., Andreassen, O.A., and Westlye, L.T. (2019). Oxytocin pathway gene networks in the human brain. Nat Commun 10, 668

53. Evenepoel M, Moerkerke M, Daniels N, Chubar V, Claes S, Turner J, Vanaudenaerde B, Willems L, Verhaeghe J, Prinsen J, Steyaert J, Boets B, Alaerts K. Endogenous oxytocin levels in children with autism: Associations with cortisol levels and oxytocin receptor gene methylation. Transl Psychiatry. 2023 Jun 30;13(1):235. doi: 10.1038/s41398-023-02524-0.

54. Jurek B, Neumann ID. The oxytocin receptor: from intracellular signaling to behavior. Physiol Rev. 2018;98:1805–908. doi: 10.1152/physrev.00031.2017.

55. 7.Bartz JA, Zaki J, Bolger N, Ochsner KN. Social effects of oxytocin in humans: context and person matter. Trends Cogn Sci. 2011;15:301–9. doi: 10.1016/j.tics.2011.05.002.

56. 8.Bakermans-Kranenburg MJ, van IJzendoorn MH. Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy. Transl Psychiatry. 2013;3:1–14.. doi: 10.1038/tp.2013.34

57. Danoff JS, Connelly JJ, Morris JP, Perkeybile AM. An epigenetic rheostat of experience: DNA methylation of OXTR as a mechanism of early life allostasis. Compr Psychoneuroendocrinol. 2021;8:100098. doi: 10.1016/j.cpnec.2021.100098.

58. Gregory SG, Connelly JJ, Towers AJ, Johnson J, Biscocho D, Markunas CA, et al. Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. BMC Med. 2009;7. 10.1186/1741-7015-7-62.

59. Peñagarikano O, Lázaro MT, Lu XH, Gordon A, Dong H, Lam HA et al. Exogenous and evoked oxytocin restores social behavior in the Cntnap2 mouse model of autism. Sci Transl Med. 2015;7. 10.1126/SCITRANSLMED.3010257.

60. 10.Silverman JL, Yang M, Turner SM, Katz AM, Bell DB, Koenig JI, et al. Low stress reactivity and neuroendocrine factors in the BTBR T+tf/J mouse model of autism. Neuroscience. 2010;171:1197–208. doi: 10.1016/j.neuroscience.2010.09.059.

61. Schaller F, Watrin F, Sturny R, Massacrier A, Szepetowski P, Muscatelli F. A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene. Hum Mol Genet. 2010;19:4895–905. doi: 10.1093/hmg/ddq424.

62. Feng L, Wong JCM, Mahendran R, Chan ESY, Spencer MD. Intranasal oxytocin for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2017 Jan 20;2017(1):CD010928. doi: 10.1002/14651858.CD010928.pub2.

63. E Hollander, et al., Oxytocin increases retention of social cognition in autism. Biol Psychiatry 61, 498–503 (2007).

64. AJ Guastella, et al., Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 67, 692–694 (2010).

65. E Andari, et al., Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci USA 107, 4389–4394 (2010).

66. R Landgraf, ID Neumann, Vasopressin and oxytocin release within the brain: A dynamic concept of multiple and variable modes of neuropeptide communication. Front Neuroendocrinol 25, 150–176 (2004).

67. Carson DS, et al. Cerebrospinal fluid and plasma oxytocin concentrations are positively correlated and negatively predict anxiety in children. Mol Psychiatry. 2015;20:1085–1090. doi: 10.1038/mp.2014.132

68. Zhuang Q, Zheng X, Yao S, Zhao W, Becker B, Xu X, Kendrick KM. Oral Administration of Oxytocin, Like Intranasal Administration, Decreases Top-Down Social Attention. Int J Neuropsychopharmacol. 2022 Nov 17;25(11):912-923. doi: 10.1093/ijnp/pyac059. PMID: 36053298; PMCID: PMC9670742.

69. Yenkoyan K, Ounanian Z, Mirumyan M, Hayrapetyan L, Zakaryan N, Sahakyan R, Bjørklund G. Advances in the Treatment of Autism Spectrum Disorder: Current and Promising Strategies. Curr Med Chem. 2024;31(12):1485-1511. doi: 10.2174/0109298673252910230920151332.

70. Alexander MV, Wang MJ, Srivastava A, Tummala S, Abbas D, Young S, Claus L, Yarrington C, Comfort A. Association between duration of intrapartum oxytocin exposure and obstetric hemorrhage. Arch Gynecol Obstet. 2024 Feb;309(2):491-501. doi: 10.1007/s00404-022-06901-w. Epub 2023 Feb 12.

71. Flanagan JC, Sippel LM, Wahlquist A, Moran-Santa Maria MM, Back SE. Augmenting Prolonged Exposure therapy for PTSD with intranasal oxytocin: A randomized, placebo-controlled pilot trial. J Psychiatr Res. 2018 Mar;98:64-69. doi: 10.1016/j.jpsychires.2017.12.014. Epub 2017 Dec 26. PMID: 29294429; PMCID: PMC5800951.

72. Atrooz F, Alkadhi KA, Salim S. Understanding stress: Insights from rodent models. Curr Res Neurobiol. 2021 May 23;2:100013. doi: 10.1016/j.crneur.2021.100013. PMID: 36246514; PMCID: PMC9559100.

73. Horta M, Kaylor K, Feifel D, Ebner NC. Chronic oxytocin administration as a tool for investigation and treatment: A cross-disciplinary systematic review. Neurosci Biobehav Rev. 2020 Jan;108:1-23. doi: 10.1016/j.neubiorev.2019.10.012. Epub 2019 Oct 21. PMID: 31647964; PMCID: PMC6949379.

74. Horta M, Kaylor K, Feifel D, Ebner NC. Chronic oxytocin administration as a tool for investigation and treatment: A cross-disciplinary systematic review. Neurosci Biobehav Rev. 2020 Jan;108:1-23. doi: 10.1016/j.neubiorev.2019.10.012. Epub 2019 Oct 21. PMID: 31647964; PMCID: PMC6949379.

75. Kong XJ, Liu J, Liu K, Koh M, Sherman H, Liu S, Tian R, Sukijthamapan P, Wang J, Fong M, Xu L, Clairmont C, Jeong MS, Li A, Lopes M, Hagan V, Dutton T, Chan SP, Lee H, Kendall A, Kwong K, Song Y. Probiotic and Oxytocin Combination Therapy in Patients with Autism Spectrum Disorder: A Randomized, Double-Blinded, Placebo-Controlled Pilot Trial. Nutrients. 2021 May 5;13(5):1552. doi: 10.3390/nu13051552.

76. Erdman S., Poutahidis T. Microbes and Oxytocin. International Review of Neurobiology. 2016;131:91–126. doi: 10.1016/bs.irn.2016.07.004.

77. Davari S., Talaei S.A., Alaei H., Salami M. Probiotics treatment improves diabetes-induced impairment of synaptic activity and cognitive function: Behavioral and electrophysiological proofs for microbiome–gut-brain axis. Neuroscience. 2013;240:287–296. doi: 10.1016/j.neuroscience.2013.02.055

78. Pobbe R.L., Pearson B.L., Defensor E.B., Bolivar V.J., Young W.S., Lee H.-J., Blanchard D.C., Blanchard R.J. Oxytocin receptor knockout mice display deficits in the expression of autism-related behaviors. Horm. Behav. 2012;61:436–444. doi: 10.1016/j.yhbeh.2011.10.010.

79. Teng B.L., Nikolova V.D., Riddick N.V., Agster K.L., Crowley J.J., Baker L.K., Koller B.H., Pedersen C.A., Jarstfer M.B., Moy S.S. Reversal of social deficits by subchronic oxytocin in two autism mouse models. Neuropharmacol. 2016;105:61–71. doi: 10.1016/j.neuropharm.2015.12.025

80. Kereszturi É. Diversity and Classification of Genetic Variations in Autism Spectrum Disorder. Int J Mol Sci. 2023 Nov 26;24(23):16768. doi: 10.3390/ijms242316768.

81. Borland JM, Rilling JK, Frantz KJ, Albers HE. Sex-dependent regulation of social reward by oxytocin: an inverted U hypothesis. Neuropsychopharmacology. 2019 Jan;44(1):97-110. doi: 10.1038/s41386-018-0129-2. Epub 2018 Jun 23.

82. Douglas LA, Varlinskaya EI, Spear LP. Rewarding properties of social interactions in adolescent and adult male and female rats: impact of social versus isolate housing of subjects and partners. Dev Psychobiol. 2004;45:153–62. doi: 10.1002/dev.20025.

83. Maud, C., Ryan, J., McIntosh, J.E. et al. The role of oxytocin receptor gene (OXTR) DNA methylation (DNAm) in human social and emotional functioning: a systematic narrative review. BMC Psychiatry 18, 154 (2018). https://doi.org/10.1186/s12888-018-1740-9

84. Zhang R. Oxytocin - A key to aetiology and treatment for Autism Spectrum Disorder. EBioMedicine. 2022 Jul;81:104126. doi: 10.1016/j.ebiom.2022.104126. Epub 2022 Jun 24. PMID: 35759921; PMCID: PMC9250000.